摘要
目的探讨PD-1抑制剂联合奥沙利铂和5-氟尿嘧啶(FOLFOX4)化疗方案治疗晚期胃癌的效果。方法选取2016年2月—2019年5月中国人民解放军联勤保障部队第九六〇医院收治的晚期胃癌患者80例为研究对象,依据随机数字表法将其分为对照组和研究组,每组40例。对照组采用FOLFOX4化疗方案治疗,研究组在对照组的基础上联合PD-1抑制剂治疗。比较两组疗效、免疫功能、血清肿瘤学指标及不良反应。结果研究组总有效率高于对照组(P<0.05)。治疗后,两组癌胚抗原、糖类抗原(CA)125、CA199低于治疗前,且研究组低于对照组(P<0.05)。治疗后,两组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平低于治疗前,CD8^(+)高于治疗前;研究组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)高于对照组,CD8^(+)低于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论PD-1抑制剂与FOLFOX4化疗方案联合治疗晚期胃癌效果显著,可阻止肿瘤扩散,减轻免疫抑制,安全有效。
Objective To investigate the efficacy of PD-1 inhibitor combined with Oxaliplatin and 5-fluorouracil(FOLFOX4)chemotherapy regimens in the treatment of advanced gastric cancer.Methods A total of 80 patients with advanced gastric cancer who admitted to the 960th Hospital of the Joint Logistic Support Force of the Chinese People’s Liberation Army from February 2016 to May 2019 were selected as study objects.They were divided into control group and study group,with 40 cases in each group.Control group was treated with FOLFOX4 chemotherapy regimens,and study group was treated with PD-1 inhibitor on the basis of control group.The curative effect,immune function,serum oncology indexes and adverse reactions were compared between two groups.Results The total effective rate of study group was higher than that of control group(P<0.05).After treatment,carcinoembryonic antigen,carbohydrate antigen(CA)125,and CA199 in two groups were lower than those before treatment,and study group was lower than control group(P<0.05).After treatment,the levels of CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)in both groups were lower than before treatment,and CD8^(+)was higher than before treatment.The levels of CD3^(+),CD4^(+),and CD4^(+)/CD8^(+)in study group were higher than those in control group,and CD8^(+)was lower than those in control group(P<0.05).There was no significant difference in the incidence of adverse reaction between two groups(P>0.05).Conclusion The combination of PD-1 inhibitor and FOLFOX4 chemotherapy regimens in the treatment of advanced gastric cancer have a significant effect,which can prevent tumor proliferation,reduce immunosuppression,and are safe and effective.
作者
郑桂丽
梁秀菊
董敏
时延龙
魏炎
仲晨
ZHENG Guili;LIANG Xiuju;DONG Min;SHI Yanlong;WEI Yan;ZHONG Chen(Department of Oncology,the 960th Hospital of the Joint Logistic Support Force of the Chinese People’s Liberation Army,Shandong Province,Ji’nan250031,China)
出处
《中国医药导报》
CAS
2021年第8期98-101,共4页
China Medical Herald
基金
山东省医药卫生科技发展计划项目(2017WS748)。
